Login Register Cart 0
Generic placeholder image

Central Nervous System Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5249
ISSN (Online): 1875-6166

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Effects of Vitamin D3 and Melatonin Combination on Pentylenetetrazole- induced Seizures in Mice

Author(s): Azam Hosseinzadeh, Ehsan Dehdashtian, Majid Jafari-Sabet and Saeed Mehrzadi*

Volume 22, Issue 2, 2022

Published on: 06 July, 2022

Page: [118 - 124] Pages: 7

DOI: 10.2174/1871524922666220429121253

Price: $65

Abstract

Background: Epileptic seizures are associated with the overproduction of free radicals in the brain leading to neuronal cell death. Therefore, reduction of oxidative stress may inhibit seizure- induced neuronal cell damage. The current study evaluated the effects of Vit D3 and melatonin and their combination on pentylenetetrazol (PTZ)-induced tonic-clonic seizures in mice.

Methods: Animals were divided into six groups. Group I was administered with normal saline (0.5 ml, intraperitoneally (i.p.)) on the 15th day of the experiment. Group II was injected with PTZ (60 mg/kg dissolved in 0.5 ml normal saline, i.p) on the 15th day. Groups III-IV were treated with diazepam (4 mg/kg/day), Vit D3 (6000 IU/kg/day), melatonin (20 mg/kg/day), and Vit D3 (6000 IU/kg/day)/melatonin (20 mg/kg/day), respectively, and were then injected with PTZ (60 mg/kg) on the 15th day of the experiment. Immediately after the injection of PTZ on the 15th day, mice were observed for a 30-min period to measure seizure latency and duration. For determination of oxidative stress markers, malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were measured in mouse brains.

Results: Treatment with Vit D3, melatonin, and Vit D3/melatonin significantly increased seizure latency and decreased seizure duration. The brain level of MDA was lower, and SOD activity was greater than in the PTZ group. Mice treated with Vit D3/melatonin had lower seizure duration than other treated groups.

Conclusions: The combination of Vit D3 and melatonin may reduce seizure frequency in epileptic patients; this effect may result from various mechanisms, including inhibition of oxidative stress.

Keywords: Seizures, epilepsy, melatonin, vitamin D3, oxidative stress, pharmacology.

« Previous Next »
Graphical Abstract

[1]
Mehrzadi, S.; Sadr, S.; Hosseinzadeh, A.; Gholamine, B.; Shahbazi, A. FallahHuseini, H.; Ghaznavi, H. Anticonvulsant activity of the ethanolic extract of Punica granatum L. seed. Neurol. Res., 2015, 37(6), 470-475.
[http://dx.doi.org/10.1179/1743132814Y.0000000460] [PMID: 25413687]
[2]
Bagheri, S.; Heydari, A.; Alinaghipour, A.; Salami, M. Effect of probiotic supplementation on seizure activity and cognitive performance in PTZ-induced chemical kindling. Epilepsy Behav., 2019, 95, 43-50.
[http://dx.doi.org/10.1016/j.yebeh.2019.03.038] [PMID: 31026781]
[3]
Yu, J-T.; Liu, Y.; Dong, P.; Cheng, R-E.; Ke, S-X.; Chen, K-Q.; Wang, J.J.; Shen, Z.S.; Tang, Q.Y.; Zhang, Z. Up-regulation of antioxidative proteins TRX1, TXNL1 and TXNRD1 in the cortex of PTZ kindling seizure model mice. PLoS One, 2019, 14(1), e0210670.
[http://dx.doi.org/10.1371/journal.pone.0210670] [PMID: 30677045]
[4]
Xu, Z.; Jing, X.; Li, G.; Sun, J.; Guo, H.; Hu, Y.; Sun, F.; Wen, X.; Chen, F.; Wang, T.; Lu, X.P. Valproate decreases vitamin D levels in pediatric patients with epilepsy. Seizure, 2019, 71, 60-65.
[http://dx.doi.org/10.1016/j.seizure.2019.06.009] [PMID: 31207394]
[5]
Görlach, A.; Bertram, K.; Hudecova, S.; Krizanova, O. Calcium and ROS: A mutual interplay. Redox Biol., 2015, 6, 260-271.
[http://dx.doi.org/10.1016/j.redox.2015.08.010] [PMID: 26296072]
[6]
Mehrzadi, S.; Hemati, K.; Reiter, R.J.; Hosseinzadeh, A. Mitochondrial dysfunction in age-related macular degeneration: Melatonin as a potential treatment. Expert Opin. Ther. Targets, 2020, 24(4), 359-378.
[http://dx.doi.org/10.1080/14728222.2020.1737015] [PMID: 32116056]
[7]
Roganovic, M.; Pantovic, S.; Dizdarevic, S. Role of the oxidative stress in the pathogenesis of epilepsy. Brain, 2019, 1, 3.
[8]
Löscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure, 2011, 20(5), 359-368.
[http://dx.doi.org/10.1016/j.seizure.2011.01.003] [PMID: 21292505]
[9]
Eddy, C.M.; Rickards, H.E.; Cavanna, A.E. The cognitive impact of antiepileptic drugs. Ther. Adv. Neurol. Disord., 2011, 4(6), 385-407.
[http://dx.doi.org/10.1177/1756285611417920] [PMID: 22164192]
[10]
Eatock, J.; Baker, G.A. Managing patient adherence and quality of life in epilepsy. Neuropsychiatr. Dis. Treat., 2007, 3(1), 117-131.
[http://dx.doi.org/10.2147/nedt.2007.3.1.117] [PMID: 19300542]
[11]
Bosak, M.; Słowik, A.; Iwańska, A.; Lipińska, M.; Turaj, W. Co-medication and potential drug interactions among patients with epilepsy. Seizure, 2019, 66, 47-52.
[http://dx.doi.org/10.1016/j.seizure.2019.01.014] [PMID: 30798113]
[12]
Johannessen, S.I.; Landmark, C.J. Antiepileptic drug interactions - principles and clinical implications. Curr. Neuropharmacol., 2010, 8(3), 254-267.
[http://dx.doi.org/10.2174/157015910792246254] [PMID: 21358975]
[13]
Martinc, B.; Grabnar, I.; Vovk, T. Antioxidants as a preventive treatment for epileptic process: A review of the current status. Curr. Neuropharmacol., 2014, 12(6), 527-550.
[http://dx.doi.org/10.2174/1570159X12666140923205715] [PMID: 25977679]
[14]
Paprocka, J.; Dec, R.; Jamroz, E.; Marszał, E. Melatonin and childhood refractory epilepsy--a pilot study. Med. Sci. Monit., 2010, 16(9), CR389-CR396.
[PMID: 20802409]
[15]
Paprocka, J.; Kijonka, M.; Pęcka, M.; Sokół, M. Melatonin in epilepsy: A new mathematical model of diurnal secretion. Int. J. Endocrinol., 2016, 2016, 3861461.
[http://dx.doi.org/10.1155/2016/3861461] [PMID: 27478439]
[16]
Kola, P.K.; Akula, A.; Nissankara Rao, L.S.; Danduga, R.C.S.R.; Mohammad, A.; Ineedi, S. Naringin in a combined therapy with phenytoin on pentylenetetrazole-induced kindling in rats. Epilepsy Behav., 2018, 89, 159-168.
[http://dx.doi.org/10.1016/j.yebeh.2018.10.006] [PMID: 30415139]
[17]
Kutluhan, S.; Naziroğlu, M.; Çelik, O.; Yilmaz, M. Effects of selenium and topiramate on lipid peroxidation and antioxidant vitamin levels in blood of pentylentetrazol-induced epileptic rats. Biol. Trace Elem. Res., 2009, 129(1-3), 181-189.
[http://dx.doi.org/10.1007/s12011-008-8287-4] [PMID: 19127351]
[18]
Littlejohns, T.J.; Kos, K.; Henley, W.E.; Kuźma, E.; Llewellyn, D.J. Vitamin D and dementia. J. Prev. Alzheimers Dis., 2016, 3(1), 43-52.
[PMID: 29214280]
[19]
Holló, A.; Clemens, Z.; Lakatos, P. Epilepsy and vitamin D. Int. J. Neurosci., 2014, 124(6), 387-393.
[http://dx.doi.org/10.3109/00207454.2013.847836] [PMID: 24063762]
[20]
Khalifah, R.A.; Hudairi, A.; Homyani, D.A.; Hamad, M.H.; Bashiri, F.A. Vitamin D supplementation to prevent vitamin D deficiency for children with epilepsy: Randomized pragmatic trial protocol. Medicine (Baltimore), 2018, 97(40), e12734.
[http://dx.doi.org/10.1097/MD.0000000000012734] [PMID: 30290685]
[21]
Şahin, S.; Gürgen, S.G.; Yazar, U.; İnce, İ.; Kamaşak, T.; Acar Arslan, E.; Diler Durgut, B.; Dilber, B.; Cansu, A. Vitamin D protects against hippocampal apoptosis related with seizures induced by kainic acid and pentylenetetrazol in rats. Epilepsy Res., 2019, 149, 107-116.
[http://dx.doi.org/10.1016/j.eplepsyres.2018.12.005] [PMID: 30584976]
[22]
Juybari, K.B.; Hosseinzadeh, A.; Ghaznavi, H.; Kamali, M.; Sedaghat, A.; Mehrzadi, S.; Naseripour, M. Melatonin as a modulator of degenerative and regenerative signaling pathways in injured retinal ganglion cells. Curr. Pharm. Des., 2019, 25(28), 3057-3073.
[http://dx.doi.org/10.2174/1381612825666190829151314] [PMID: 31465274]
[23]
Shahriari, M.; Mehrzadi, S.; Naseripour, M.; Fatemi, I.; Hosseinzadeh, A.; Kanavi, M.R. Beneficial effects of melatonin and atorvastatin on retinopathy in streptozocin-induced diabetic rats. Curr. Drug Ther., 2020, 15(4), 396-403.
[http://dx.doi.org/10.2174/1574885514666191204104925]
[24]
Pourhanifeh, M.H.; Kamali, M.; Mehrzadi, S.; Hosseinzadeh, A. Melatonin and neuroblastoma: A novel therapeutic approach. Mol. Biol. Rep., 2021, 48(5), 4659-4665.
[http://dx.doi.org/10.1007/s11033-021-06439-1] [PMID: 34061325]
[25]
Mehrzadi, S.; Karimi, M.Y.; Fatemi, A.; Reiter, R.J.; Hosseinzadeh, A. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: Beneficial effects of melatonin. Pharmacol. Ther., 2021, 224, 107825.
[http://dx.doi.org/10.1016/j.pharmthera.2021.107825] [PMID: 33662449]
[26]
Dehdashtian, E.; Hosseinzadeh, A.; Hemati, K.; Karimi, M.Y.; Fatemi, I.; Mehrzadi, S. Anti-convulsive Effect of Thiamine and Melatonin Combination in Mice: Involvement of Oxidative Stress. Cent. Nerv. Syst. Agents Med. Chem., 2021, 21(2), 125-129.
[http://dx.doi.org/10.2174/1871524921666210623161212] [PMID: 34165417]
[27]
Mehrzadi, S.; Pourhanifeh, M.H.; Mirzaei, A.; Moradian, F.; Hosseinzadeh, A. An updated review of mechanistic potentials of melatonin against cancer: Pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress. Cancer Cell Int., 2021, 21(1), 188.
[http://dx.doi.org/10.1186/s12935-021-01892-1] [PMID: 33789681]
[28]
Hemati, K.; Pourhanifeh, M.H.; Fatemi, I.; Hosseinzadeh, A.; Mehrzadi, S. Anti-degenerative effect of melatonin on intervertebral disc: Protective contribution against inflammation, oxidative stress, apoptosis, and autophagy. Curr. Drug Targets, 2022.
[http://dx.doi.org/10.2174/1389450123666220114151654] [PMID: 35034592]
[29]
Hosseinzadeh, A.; Kamrava, S.K.; Moore, B.C.J.; Reiter, R.J.; Ghaznavi, H.; Kamali, M.; Mehrzadi, S. Molecular aspects of melatonin treatment in tinnitus: A review. Curr. Drug Targets, 2019, 20(11), 1112-1128.
[http://dx.doi.org/10.2174/1389450120666190319162147] [PMID: 30892162]
[30]
Dabak, O.; Altun, D.; Arslan, M.; Yaman, H.; Vurucu, S.; Yesilkaya, E.; Unay, B. Evaluation of Plasma Melatonin Levels in Children With Afebrile and Febrile Seizures. Pediatr. Neurol., 2016, 57, 51-55.
[http://dx.doi.org/10.1016/j.pediatrneurol.2015.12.025] [PMID: 26851993]
[31]
Moezi, L.; Shafaroodi, H.; Hojati, A.; Dehpour, A.R. The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Behav., 2011, 22(2), 200-206.
[http://dx.doi.org/10.1016/j.yebeh.2011.07.002] [PMID: 21840768]
[32]
Institute of Laboratory Animal R. Committee on C, Use of Laboratory A, National Institutes of H, Division of Research R. Guide for the care and use of laboratory animals U.S. Dept. of Health and Human Services, Public Health Service, National Insititutes of Health: Bethesda, Md; , 1985.
[33]
Goldberg-Stern, H.; Oren, H.; Peled, N.; Garty, B-Z. Effect of melatonin on seizure frequency in intractable epilepsy: A pilot study. J. Child Neurol., 2012, 27(12), 1524-1528.
[http://dx.doi.org/10.1177/0883073811435916] [PMID: 22378657]
[34]
Mohanan, P.V.; Yamamoto, H.A. Preventive effect of melatonin against brain mitochondria DNA damage, lipid peroxidation and seizures induced by kainic acid. Toxicol. Lett., 2002, 129(1-2), 99-105.
[http://dx.doi.org/10.1016/S0378-4274(01)00475-1] [PMID: 11879979]
[35]
Bikjdaouene, L.; Escames, G.; León, J.; Ferrer, J.M.; Khaldy, H.; Vives, F.; Acuña-Castroviejo, D. Changes in brain amino acids and nitric oxide after melatonin administration in rats with pentylenetetrazole-induced seizures. J. Pineal Res., 2003, 35(1), 54-60.
[http://dx.doi.org/10.1034/j.1600-079X.2003.00055.x] [PMID: 12823614]
[36]
Mohammadi, F.; Shakiba, S.; Mehrzadi, S.; Afshari, K.; Rahimnia, A.H.; Dehpour, A.R. Anticonvulsant effect of melatonin through ATP-sensitive channels in mice. Fundam. Clin. Pharmacol., 2020, 34(1), 148-155.
[http://dx.doi.org/10.1111/fcp.12490] [PMID: 31197879]
[37]
León, J.; Macías, M.; Escames, G.; Camacho, E.; Khaldy, H.; Martín, M.; Espinosa, A.; Gallo, M.A.; Acuña-Castroviejo, D. Structure-related inhibition of calmodulin-dependent neuronal nitric-oxide synthase activity by melatonin and synthetic kynurenines. Mol. Pharmacol., 2000, 58(5), 967-975.
[http://dx.doi.org/10.1124/mol.58.5.967] [PMID: 11040043]
[38]
Muñoz-Hoyos, A.; Molina-Carballo, A.; Macías, M.; Rodríguez-Cabezas, T.; Martín-Medina, E.; Narbona-López, E.; Valenzuela-Ruiz, A.; Acuña-Castroviejo, D. Comparison between tryptophan methoxyindole and kynurenine metabolic pathways in normal and preterm neonates and in neonates with acute fetal distress. Eur. J. Endocrinol., 1998, 139(1), 89-95.
[http://dx.doi.org/10.1530/eje.0.1390089] [PMID: 9703384]
[39]
Holló, A; Clemens, Z; Kamondi, A; Lakatos, P; Szűcs, A. Correction of vitamin D deficiency improves seizure control in epilepsy: A pilot study. Epilepsy Behavior : E&B, 2012, 24(1), 131-3.
[http://dx.doi.org/10.1016/j.yebeh.2012.03.011]
[40]
Kalueff, A.V.; Minasyan, A.; Keisala, T.; Kuuslahti, M.; Miettinen, S.; Tuohimaa, P. Increased severity of chemically induced seizures in mice with partially deleted Vitamin D receptor gene. Neurosci. Lett., 2006, 394(1), 69-73.
[http://dx.doi.org/10.1016/j.neulet.2005.10.007] [PMID: 16256271]
[41]
Pendo, K.; DeGiorgio, C.M. Vitamin D3 for the Treatment of Epilepsy: Basic Mechanisms, Animal Models, and Clinical Trials. Front. Neurol., 2016, 7, 218.
[http://dx.doi.org/10.3389/fneur.2016.00218] [PMID: 28008324]
[42]
Kalueff, A.V.; Minasyan, A.; Tuohimaa, P. Anticonvulsant effects of 1,25-dihydroxyvitamin D in chemically induced seizures in mice. Brain Res. Bull., 2005, 67(1-2), 156-160.
[http://dx.doi.org/10.1016/j.brainresbull.2005.06.022] [PMID: 16140175]
[43]
Rauca, C.; Wiswedel, I.; Zerbe, R.; Keilhoff, G.; Krug, M. The role of superoxide dismutase and α-tocopherol in the development of seizures and kindling induced by pentylenetetrazol - influence of the radical scavenger α-phenyl-N-tert-butyl nitrone. Brain Res., 2004, 1009(1-2), 203-212.
[http://dx.doi.org/10.1016/j.brainres.2004.01.082] [PMID: 15120598]
[44]
Proietti, S.; Cucina, A.; D’Anselmi, F.; Dinicola, S.; Pasqualato, A.; Lisi, E.; Bizzarri, M. Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J. Pineal Res., 2011, 50(2), 150-158.
[PMID: 21091766]
[45]
Alamro, A.A.; Al-Malky, M.M.; Ansari, M.G.A.; Amer, O.E.; Alnaami, A.M.; Hussain, S.D. The effects of melatonin and vitamin D3 on the gene expression of BCl-2 and BAX in MCF-7 breast cancer cell line. J. King Saud Univ. Sci., 2021, 33(2), 101287.
[http://dx.doi.org/10.1016/j.jksus.2020.101287]
[46]
Sezgin, G.; Oztürk, G.; Güney, S.; Sinanoğlu, O.; Tunçdemir, M. Protective effect of melatonin and 1,25-dihydroxyvitamin D3 on renal ischemia-reperfusion injury in rats. Ren. Fail., 2013, 35(3), 374-379.
[http://dx.doi.org/10.3109/0886022X.2012.760409] [PMID: 23356461]
[47]
Sahakyan, G. The role of Vitamin D in treatment of Chronic Insomnia with Melatonin (P5. 320) 2018.

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy